BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Insilico Medicine

Insilico Medicine logo

Founded
2014
Patents
11
Publications
128

Technologies

AI Companies (Drug Discovery)

A company dedicated to finding novel solutions for aging and age-related diseases using advances in genomics and big data analysis.

Our mission statement and our pledge to our investors, friends and families: Through excellence in knowledge management, machine learning and bioinformatics, relentless pursuit for new drug, omics and clinical outcomes data, development of reliable in silico drug screening methods, novel validation approaches and strong international partnerships in personalized medicine we strive to find real working solutions to cure and prevent age-related diseases and aging itself.

This mission will be achieved within within the regulatory frameworks as well as the legal and ethical boundaries and by working with the outstanding scientists, academic and medical institutions and pharmaceutical companies of impeccable credibility.

Our goals are:

- to become the first and the largest drug discovery company in aging and age-related diseases;
- to become the first company to fully implement the concept of personalized science, where medicine is developed, tested and validated for individual patients in a safe high-throughput environment

reinforcement learning drug development Generative adversarial networks biomarker development longevity aging


Posts Mentioning This Company

A Race For Better 3CL Inhibitors to Cure COVID-19: Copies vs. Innovators

  
Disclaimer: This post is not medical advice and is for informational purposes only. All the information contained here is related to research and development and is not intended for clinical use. Never attempt to take any medications without consulting with your medical doctor.    The global COVID-19 pandemic is far …

9 Companies Using Artificial Intelligence to Fight Infectious Diseases

  
Development of a novel drug is a tedious process that requires immense investments of resources and time - on average, it takes at least ten years and $ 2.6 B for a new medicine to complete the journey from initial discovery to the marketplace. And then patents give pharmaceutical companies …

Building Momentum for Global AI-driven Longevity Transformation

  
Today, Insilico Medicine, a leading player in artificial intelligence (AI)-driven drug discovery and longevity research, tops up its recent $60 million Series D with additional $35 million from Prosperity7 Ventures, a global VC fund by Saudi Arabia’s giant Aramco. This investment by Aramco is yet another step within Saudi Arabia’s …

15 Biopharma Research Trends to Watch in 2022

  
Table of contents:    mRNA vaccines and RNA therapies  Epitranscriptomics Targeting RNA with small molecules Deep learning and big data in drug discovery Neoantigens Theranostics  Exosomes Synthetic Biology 3D Bioprinting Antibiotics “anti-trend” (and hope?) Nanotechnologies in Drug Delivery Gene Editing (CRISPR-Cas9) Aging research  Microbiome  Protein Degraders   Discoveries made in …

AI Helps Discover Potential First-in-class Molecule for Immuno-oncology for Fosun Pharma

  
The global artificial intelligence (AI) leader Insilico Medicine announced its first milestone in cancer immunotherapy for their external collaboration with Fosun Pharmaceuticals (600196.SH, 02196.HK), an international healthcare group in China. In under 40 days since the collaboration announcement, companies nominated the first preclinical drug candidate ISM004-1057D, a potential first-in-class small …

Pharmaceutical AI in 2021: Key Developments So Far

  
Table of Contents:   Introduction Artificial intelligence (AI) in drug discovery yields breakthroughs The abundance of venture capital, major funding rounds IPOs of AI Pharma Companies in 2021 New AI-driven biotech startups founded in 2020 Notable AI-focused collaborations involving “big pharma” players AI adoption by the contract research organizations (CROs)  …

Contract Research Organizations Tap Into AI To Increase Value Proposition

  
A few decades ago, pharmaceutical giants did most of the discovery work in-house, along with every other work necessary to get a drug or medical device to market. Nowadays, nearly any type of R&D or regulatory filing work that a drug maker or a medical-device producer needs to do -- …

The Increasing Potential of Virtual Reality in Drug Design

  
Using virtual reality (VR) for manipulating 3D models of molecules in the context of drug design is an emerging technological opportunity, which increasingly grabs attention among scientists at biotech startups, and larger pharmaceutical organizations. 

How Pharma Reacts To Wuhan Coronavirus Outbreak

  
UPDATE April 04. 2020. The number of confirmed cases of COVID19 approaches 1M globally. Since too many drug repurposing programs and vaccine development projects have been urgently initiated, we decided to summarize them in a separate post: A Running List Of COVID-19 Treatments And Vaccines In Development With this, we …

Artificial Intelligence Yields Early Results in Drug Discovery

  
A historically significant milestone has just been reached by Oxford, UK-based Exscientia, which used its artificial intelligence (AI)-based drug discovery platform Centaur Chemist™ to deliver the first drug candidate in the framework of their multiyear collaboration with GSK. This AI-derived small molecule is a highly potent in vivo active substance …

How Big Pharma Adopts AI To Boost Drug Discovery

  
(Last updated 08.10.2018) The type of artificial intelligence (AI) which scares some of the greatest minds, like Elon Musk and Stephen Hawking, is called “general artificial intelligence” -- the one which can “think” pretty much like humans do, and which can quickly evolve into a dangerous “superintelligence”. There is a …

Pharma and Healthcare AI Vendors Join Forces To Accelerate Progress In Drug Discovery

  
Today Basel is crowded with some of the top business and research leaders representing a young and rapidly growing industry of artificial intelligence (AI) in healthcare and pharmaceutical research. They come together to announce mission and launch activities of a global Alliance for Artificial Intelligence in Healthcare (AAIH), which is …

2018 Brings A Surge Of Activity In The “AI For Drug Discovery” Space

  
(Last updated: 15.03.2018) The idea of using artificial intelligence (AI) to accelerate drug discovery process and boost a success rate of pharmaceutical research programs has inspired a notable amount of activity over the last several years with a considerable number of initiated research collaborations between AI-driven R&D vendors and top …
SHARE